Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Environment
Akira Endo's Contributions
August 17, 2009
| A version of this story appeared in
Volume 87, Issue 33
The book review of "Triumph of the Heart" by John Lamattina, and particularly the role of Akira Endo in finding an HMGCoA reductase inhibitor, reminds me of the story that went around some 20 to 25 years ago (C&EN, June 8, page 61).
The only difference between compactin, Endo's original isolate from fermentations, and lovastatin, the first statin approved for clinical use from Merck, is one methyl group—and a patent. And so an industry was born.
Kenneth E. Neet
North Chicago, Ill.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter